← Human Trials & Peer-Reviewed Studies
Vitamin D Supplementation and Survival of Patients with Non-small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial.
Plain-language guide to PMID 30018118 (2018): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc.
Key Facts
- PMID
- 30018118
- Journal
- Clinical cancer research : an official journal of the American Association for Cancer Research
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Akiba T et al. (12 authors)
- DOI
- 10.1158/1078-0432.CCR-18-0483
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.
The primary and secondary outcomes were relapse-free survival (RFS) and overall survival (OS), respectively.
Prespecified subgroup analyses were performed with stratification by stage (early vs. advanced), pathology (adenocarcinoma vs. others), and 25(OH)D levels (low, <20 ng/mL vs. high, ≥20 ng/mL).
Who Took Part
By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.
Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.
The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.
What Was Measured
The primary and secondary outcomes were relapse-free survival (RFS) and overall survival (OS), respectively.
Prespecified subgroup analyses were performed with stratification by stage (early vs. advanced), pathology (adenocarcinoma vs. others), and 25(OH)D levels (low, <20 ng/mL vs. high, ≥20 ng/mL).
PubMed files the paper under topics including Adenocarcinoma of Lung, CDX2 Transcription Factor, Carcinoma, Non-Small-Cell Lung, DNA-Binding Proteins, Dietary Supplements, Disease-Free Survival and Neoplasm Recurrence, Local.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.
The publication is from 2018 (Clinical cancer research : an official journal of the American Association for Cancer Research), a journal based in United States.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.